NewAmsterdam Pharma
Headquarters country
Netherlands
Registry sponsor category
Industry
- Other names
- NewAmsterdam Pharma
- Company name
- NewAmsterdam Pharma
- Organisation type
- Industry
- Registered legal name
- NewAmsterdam Pharma Company N.V.
- US industry code (SIC)
- Pharmaceutical preparations
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001936258
- Legal Entity Identifier (LEI)
- 984500B6549TF6E14D36
Related records
Trials (20)
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
- A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
- A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
- A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
- Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
- Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
- Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
- Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
- Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
- Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
- Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
- PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
- Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
- Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
- Randomized Study of Obicetrapib in Combination With Ezetimibe
- Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
- Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy